Occupational Allergic Rhinitis: What Do We Know?

被引:0
|
作者
Mungan D. [1 ]
机构
[1] Department of Pulmonary Diseases, Division of Allergy and Immunology, School of Medicine, Ankara University, Ankara
关键词
Occupational allergy; Occupational asthma; Occupational rhinitis; Rhinitis; Work related rhinitis;
D O I
10.1007/s40521-014-0041-x
中图分类号
学科分类号
摘要
• The main objectives of the management of occupational rhinitis are, elimination of symptoms and prevention of development of asthma. • Management strategies include, environmental interventions (cessation or reducing the exposure to the causal agent) and appropriate pharmacologic treatment. • Drug therapy does not differ from non-occupational rhinitis. • Given the increased risk for occupational asthma in patients with occupational rhinitis, the most effective approach is complete avoidance of exposure to the offending agent. However, if complete cessation of exposure leads to adverse socio-economic measures, reduction in contact with the agent in combination with drug therapy can be considered. • Allergen immunotherapy (AIT) has been used for a few sensitizers in occupational allergic diseases. The use of AIT is very limited due to inadequate standardization of occupational allergens. Effective treatment of patients with occupational allergy by the use of AIT may allow workers to continue their work when exposure can not be avoided. The new technologies are expected to improve the quality and efficacy of specific immunotherapy in patients with occupational allergy in the future. © 2014, Springer International Publishing AG.
引用
收藏
页码:10 / 19
页数:9
相关论文
共 50 条
  • [1] Allergic Rhinitis: What Do We Know About Allergen-Specific Immunotherapy?
    Boonpiyathad, Tadech
    Lao-Araya, Mongkol
    Chiewchalermsri, Chirawat
    Sangkanjanavanich, Sasipa
    Morita, Hideaki
    FRONTIERS IN ALLERGY, 2021, 2
  • [2] What we know and what we do not know
    McDonald, JC
    RADIATION PROTECTION DOSIMETRY, 2005, 113 (02) : 127 - 128
  • [3] We do not know what we do not know
    Spaeth, GL
    OPHTHALMIC SURGERY AND LASERS, 1999, 30 (05): : 337 - 340
  • [4] Biologic prosthesis allergic sensitization: What do we (not) know?
    Radice, A.
    Iorno, M. L. C.
    Meucci, E.
    Fassio, F.
    Manfredi, M.
    Macchia, D.
    ALLERGY, 2018, 73 : 499 - 499
  • [5] We know what they think, but do we know what they do?
    Callingham, M
    Baker, T
    INTERNATIONAL JOURNAL OF MARKET RESEARCH, 2002, 44 (03) : 299 - 335
  • [6] What do we know? What do we need to know?
    Milena J. Henzlova
    W. Lane Duvall
    Journal of Nuclear Cardiology, 2017, 24 : 252 - 254
  • [7] What do we know? What do we need to know?
    Henzlova, Milena J.
    Duvall, W. Lane
    JOURNAL OF NUCLEAR CARDIOLOGY, 2017, 24 (01) : 252 - 254
  • [8] OCCUPATIONAL-CANCER IN CANADA - WHAT DO WE KNOW
    TESCHKE, K
    BARROETAVENA, MC
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1992, 147 (10) : 1501 - 1507
  • [9] Genetic platforms: Do we do what we know? or do we know what we do?
    Bernet, Laia
    Pla, Maria Jesus
    Janez, Noelia Martinez
    REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2021, 34 (02): : 100 - 110
  • [10] Quasicrystals: What do we know? What do we want to know? What can we know?
    Steurer, Walter
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2018, 74 : 1 - 11